Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Moxonidine (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- 04 Nov 2013 Planned end date changed from 1 Sep 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 25 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 Aug 2010 New trial record